May 18, 2021 11:39am
Germany-based Merck KGaA saw an 8.6% increase in sales in 2020 and looks for even more success with reorganization of its healthcare unit in North America as it tries to spur sales of Mavenclad, Bavencio and Tepmetko. (Fierce Pharma)
Belen Garijo took over last month as CEO at Merck KGaA and she’s not wasting time putting her imprint on the company.
On Tuesday, the Germany-based company said it had tapped Chris Round as president at its North America healthcare unit, replacing Andrew Patterson, who'll step into the brand-new role of chief marketing officer.
By beefing up its leadership in the United States, Merck aims to help EMD Serono cash in with three promising drugs––its Pfizer-partnered immuno-oncology drug Bavencio, multiple sclerosis treatment Mavenclad and Tepmetko for non-small cell lung cancer.